Concepedia

Pietro Taverna

PT

Statistics

Publications

51

Citations

3.1K

H-Index

30

Active since

1991

Affiliations

Astex Pharmaceuticals(Current)

The University of Texas MD Anderson Cancer Center

Plex Pharmaceuticals (United States)

Sunesis (United States)

Roswell Park Comprehensive Cancer Center

Pietro Taverna is an author at Astex Pharmaceuticals specializing in medicine, oncology, and pharmacology.

Publications per year

1991–2023

51

Publications

51

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 281 citations · Full text

, , +13

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

Lili Liu, Pietro Taverna, Cecilia M. Whitacre et al. · PubMed · 1999 · 163 citations

, , +17

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

Lisa S. Chen, Sanjeev Redkar, Pietro Taverna et al. · Blood · 2011 · 162 citations · Full text

, , +14

Epigenetic Targeting of Ovarian Cancer Stem Cells

Yinu Wang, Horacio Cárdenas, Fang Fang et al. · Cancer Research · 2014 · 161 citations · Full text

, , +13

Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli

Pietro Taverna, Barbara Sedgwick · Journal of Bacteriology · 1996 · 158 citations · Full text

, , +16

1–5 of 51